It is widely recognized that the efficacy of canonical cancer therapies could be improved by IDH1 inhibition.[44] In pancreatic cancer cells, gemcitabine treatment induces HuR‐dependent IDH1 expression, and the HuR‐IDH1 regulatory axis in turn results in pancreatic cancer cell chemoresistance. Here, ELAVL1 is linked to cancer.